Saturday, February 29 (26)

8:00 AM–9:00 AM

General Session III

Pain Management in Dogs and Cats: Implications for Treating People

Mark Epstein

This session will also examine the One Pain concept, including the translational impact (and prospects) of animal pain as encountered in veterinary medicine and the relationship to its human counterpart in the research and clinical settings. Discussions will include recognition and assessment of pain in animals; an emerging focus on natural models of painful conditions in animals to analogous conditions in humans, the impact of the opioid crisis in veterinary medicine, veterinary organizations, initiatives, and guidelines focused on animal pain, a snapshot of pain management strategies that can be found in primary care veterinary settings, and emerging directions.

Co-Presenters:

Mark Epstein

Moderator:

Patrick Tighe

7-8 AM

AJOVY® (fremanezumab-vfrm) Injection: An anti-CGRP for the Preventive Treatment of Migraine in Adults

Faculty

Charles E. Argoff , MD, CPE
Professor of Neurology
Albany Medical College
Director, Comprehensive Pain Center
Albany Medical Center
Albany, NY

Educational Objectives

After attending this symposium, participants should be better able to:

  • Provide a review of migraine impact, diagnosis, and treatment guidelines
  • Review recent information on migraine pathophysiology and the role of CGRP in ­migraine
  • Discuss clinical trial study design and background on AJOVY as an anti-CGRP for the preventive treatment of migraine in adults
  • Review the efficacy, safety, and dosing/ administration of AJOVY in clinical trials

Description

During this presentation, faculty will provide an overview of AJOVY® (fremanezumab-vfrm) injection as a preventive treatment of migraine in adults. The presentation will begin with a discussion of the migraine disease state, including migraine pathophysiology. This will be followed by a review of the efficacy and safety of AJOVY. Additionally, participants will have the opportunity to ask questions of the faculty.

IMPORTANT SAFETY_INFORMATION (continued)

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy.

Adverse Reactions: The most common adverse reactions (_5% and greater than placebo) were injection site reactions.

Activity sponsored by: Teva Pharmaceuticals

Subscribe to this RSS feed